Pittsburgh Compound-B and Alzheimer's Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study

被引:30
作者
Gunnarsson, M. Degerman [1 ]
Lindau, M. [1 ,6 ]
Wall, A. [3 ]
Blennow, K. [4 ]
Darreh-Shori, T. [5 ]
Basu, S. [2 ]
Nordberg, A. [5 ]
Larsson, A. [1 ]
Lannfelt, L. [1 ]
Basun, H. [7 ]
Kilander, L. [1 ]
机构
[1] Uppsala Univ, Dept Publ Hlth Geriatr, Uppsala, Sweden
[2] Uppsala Univ, Dept Publ Hlth Oxidat Stress & Inflammat, Uppsala, Sweden
[3] GE Healthcare Uppsala, Imanet PET Ctr, Uppsala, Sweden
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Alzheimer Neurobiol, Stockholm, Sweden
[6] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden
[7] BioArctic Neurosci, Stockholm, Sweden
关键词
Pittsburgh Compound-B; PET FDG; Alzheimer's disease; follow-up; Biomarkers; CSF; A beta 1-42; A beta x-42 APOE; Cystatin C; AMYLOID-BETA PROTEIN; CEREBROSPINAL-FLUID; COGNITIVE IMPAIRMENT; TAU-PROTEIN; CYSTATIN-C; WORK GROUP; DEMENTIA; BRAIN; DIAGNOSIS; PREDICTION;
D O I
10.1159/000281832
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PIB) is an in vivo ligand for measuring beta-amyloid (A beta) load. Associations between PET PIB and cerebrospinal fluid (CSF) A beta 1-42 and apolipoprotein E epsilon 4 (APOE epsilon 4) have been observed in several studies, but the relations between PIB uptake and other biomarkers of Alzheimer's disease (AD) are less investigated. Method: PET PIB, PET 18Fluoro-2-deoxy-D-glucose and different AD biomarkers were measured twice in CSF, plasma and urine 12 months apart in 10 patients with a clinical diagnosis of mild to moderate AD. Results: PIB retention was constant over 1 year, inversely related to low CSF A beta 1-42 (p = 0.01) and correlated positively to the numbers of the APOE epsilon 4 allele (0, 1 or 2) (p = 0.02). There was a relation between mean PIB retention and CSF ApoE protein (r = -0.59, p = 0.07), and plasma cystatin C (r = -0.56, p = 0.09). Conclusion: PIB retention is strongly related to CSF A beta 1-42, and to the numbers of the APOE epsilon 4 allele. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:204 / 212
页数:9
相关论文
共 63 条
[1]   Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans [J].
Andersson, JLR ;
Thurfjell, L .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1997, 21 (01) :136-144
[2]   CSF markers for Alzheimer's disease:: Total Tau, phospho-tau and Aβ42 [J].
Andreasen, N ;
Sjögren, M ;
Blennow, K .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2003, 4 (04) :147-155
[3]   Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].
Andreasen, N ;
Hesse, C ;
Davidsson, P ;
Minthon, L ;
Wallin, A ;
Winblad, B ;
Vanderstichele, H ;
Vanmechelen, E ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680
[4]  
[Anonymous], 1976, Multilingual Aphasia Examination, Revised, 1978
[5]  
BASU S, 1998, PROSTAGLANDINS LEUKO, V68, P319
[6]   The importance of impaired physical health and age in normal cognitive aging [J].
Bergman, Ingvar ;
Blomberg, Mari ;
Almkvist, Ove .
SCANDINAVIAN JOURNAL OF PSYCHOLOGY, 2007, 48 (02) :115-125
[7]   CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry [J].
Blennow, K ;
Vanmechelen, E .
BRAIN RESEARCH BULLETIN, 2003, 61 (03) :235-242
[8]   tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[9]   Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients [J].
BlumDegen, D ;
Muller, T ;
Kuhn, W ;
Gerlach, M ;
Przuntek, H ;
Riederer, P .
NEUROSCIENCE LETTERS, 1995, 202 (1-2) :17-20
[10]  
CACABELOS R, 1991, METHOD FIND EXP CLIN, V13, P455